

Current Report No 27

Planned acceleration of the Genomtec®ID platform commercialization process.

The Management Board of Genomtec S.A. („Company”, „Issuer”) hereby informs that today, i.e. on 3 November 2021, considering the prospective development of a targeted market where the Issuer operates, i.e. the diagnostic segment of rapid POC testing, reflected into Company's strategic developmental goals and publicly announced via Company's Information Documents, the Issuer has commenced an analysis on feasibility of accelerated commercialization of the Genomtec®ID platform.

The analysis will include a selection of optimal solutions supporting the strategic Company's development, primarily, determining the prime time for market entry of the Genomtec® ID platform, inclusively of its acceleration with respect to the currently announced plan. As part of the analysis, various scenarios fast-tracking Company's development will be deliberated, including possible use of existing regulations enabling faster device certification and, consequently, faster market authorization generating sales' revenue. One of the analysed variables will include commercial sale activities for Genomtec® ID to be conducted by the Company, leveraging for this purpose trading partners and determination of an appropriate time for technology out-licensing or sale its acquisition. The activities are aimed at improving Company's operational scale-up, utilizing of market and legal conditions and the Company's know-how.

The Issuer will inform about any future important stages of the process in current reports.